Payment overview · 2025
General Payments
$1,189.72
63 reported records · 15 companies
Healthcare provider profile · identity verified
Michael A Rosemore, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · HUEYTOWN, AL · NPI 1104849843
Verified facts
What the public records show
CMS Open Payments records show Michael A Rosemore, D.O. received $1,189.72 in general payments during 2025 across 63 reported records.
GlaxoSmithKline, LLC. accounted for 13.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 594 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $165.41 | 13.9% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $145.24 | 12.2% | 8 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $116.54 | 9.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $111.60 | 9.4% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $107.70 | 9.1% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $96.46 | 8.1% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $95.12 | 8.0% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $93.87 | 7.9% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $87.00 | 7.3% | 5 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $39.51 | 3.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.66 | 3.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.99 | 2.8% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.91 | 2.4% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.04 | 1.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.67 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,189.72 | 63 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $116.54 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $111.60 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $111.47 | 8 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $107.70 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $105.80 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $95.12 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $87.00 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $76.58 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $62.12 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $53.94 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $53.94 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $39.51 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $38.15 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $37.03 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.99 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $27.91 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.20 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.20 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $13.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 594 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 32 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 112 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 94 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 93 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
93 | 49 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
112 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
94 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
594 | 196 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 841 | 322 |
| Levothyroxine Sodium | Levothyroxine Sodium | 653 | 203 |
| Pantoprazole Sodium | Pantoprazole Sodium | 607 | 279 |
| Eliquis | Apixaban | 594 | 196 |
| Amlodipine Besylate | Amlodipine Besylate | 583 | 222 |
| Metoprolol Succinate | Metoprolol Succinate | 540 | 184 |
| Gabapentin | Gabapentin | 470 | 207 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 393 | 178 |
| Trazodone Hcl | Trazodone Hcl | 356 | 126 |
| Potassium Chloride | Potassium Chloride | 343 | 129 |
| Furosemide | Furosemide | 337 | 135 |
| Tamsulosin Hcl | Tamsulosin Hcl | 301 | 123 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 277 | 90 |
| Buspirone Hcl | Buspirone Hcl | 265 | 69 |
| Losartan Potassium | Losartan Potassium | 262 | 109 |
| Quetiapine Fumarate | Quetiapine Fumarate | 260 | 53 |
| Sertraline Hcl | Sertraline Hcl | 255 | 62 |
| Mirtazapine | Mirtazapine | 250 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 238 | 102 |
| Duloxetine Hcl | Duloxetine Hcl | 226 | 64 |
| Omeprazole | Omeprazole | 222 | 68 |
| Carvedilol | Carvedilol | 220 | 100 |
| Escitalopram Oxalate | Escitalopram Oxalate | 217 | 82 |
| Donepezil Hcl | Donepezil Hcl | 207 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 194 | 64 |
| Lisinopril | Lisinopril | 193 | 87 |
| Alprazolam | Alprazolam | 192 | 57 |
| Oxycodone Hcl | Oxycodone Hcl | 192 | 141 |
| Metformin Hcl | Metformin Hcl | 191 | 78 |
| Clopidogrel | Clopidogrel Bisulfate | 172 | 76 |
| Tramadol Hcl | Tramadol Hcl | 156 | 56 |
| Clonazepam | Clonazepam | 148 | 48 |
| Meloxicam | Meloxicam | 144 | 43 |
| Hydralazine Hcl | Hydralazine Hcl | 142 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 137 | 57 |
| Allopurinol | Allopurinol | 132 | 51 |
| Famotidine | Famotidine | 130 | 56 |
| Methocarbamol | Methocarbamol | 128 | 90 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 121 | 80 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 121 | 71 |
| Celecoxib | Celecoxib | 119 | 48 |
| Citalopram Hbr | Citalopram Hydrobromide | 118 | 38 |
| Lorazepam | Lorazepam | 117 | 37 |
| Xarelto | Rivaroxaban | 116 | 30 |
| Jardiance | Empagliflozin | 112 | 31 |
| Simvastatin | Simvastatin | 111 | 40 |
| Ondansetron Hcl | Ondansetron Hcl | 110 | 57 |
| Alendronate Sodium | Alendronate Sodium | 109 | 36 |
| Amiodarone Hcl | Amiodarone Hcl | 105 | 37 |
| Divalproex Sodium | Divalproex Sodium | 105 | 19 |
| Montelukast Sodium | Montelukast Sodium | 102 | 51 |
| Tizanidine Hcl | Tizanidine Hcl | 101 | 50 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 100 | 37 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 100 | 27 |
| Ozempic | Semaglutide | 94 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 93 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 93 | 49 |
| Prednisone | Prednisone | 88 | 44 |
| Januvia | Sitagliptin Phosphate | 85 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 85 | 26 |
| Glimepiride | Glimepiride | 84 | 28 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 83 | 22 |
| Baclofen | Baclofen | 83 | 25 |
| Valsartan | Valsartan | 83 | 17 |
| Levetiracetam | Levetiracetam | 82 | 31 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 80 | 17 |
| Pregabalin | Pregabalin | 77 | 36 |
| Memantine Hcl | Memantine Hcl | 75 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 74 | 63 |
| Bumetanide | Bumetanide | 73 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 26 |
| Atenolol | Atenolol | 68 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 66 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 28 |
| Fenofibrate | Fenofibrate Nanocrystallized | 61 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | 26 |
| Clonidine Hcl | Clonidine Hcl | 59 | 20 |
| Ondansetron Odt | Ondansetron | 59 | 44 |
| Lamotrigine | Lamotrigine | 57 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 55 | 17 |
| Ezetimibe | Ezetimibe | 51 | 24 |
| Primidone | Primidone | 51 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | 20 |
| Torsemide | Torsemide | 50 | 25 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 49 | suppressed |
| Bupropion Xl | Bupropion Hcl | 48 | 24 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 47 | 16 |
| Sucralfate | Sucralfate | 47 | 19 |
| Carbamazepine | Carbamazepine | 46 | suppressed |
| Latanoprost | Latanoprost | 45 | 23 |
| Enoxaparin Sodium | Enoxaparin Sodium | 43 | 41 |
| Midodrine Hcl | Midodrine Hcl | 42 | 27 |
| Spironolactone | Spironolactone | 42 | 23 |
| Olanzapine | Olanzapine | 41 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | 11 |
| Rybelsus | Semaglutide | 39 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 38 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | 21 |
| Calcitriol | Calcitriol | 37 | suppressed |
| Lansoprazole | Lansoprazole | 37 | 17 |
| Cefdinir | Cefdinir | 35 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 13 |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 35 | suppressed |
| Digoxin | Digoxin | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | 21 |
| Dutasteride | Dutasteride | 33 | suppressed |
| Timolol Maleate | Timolol Maleate | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | 18 |
| Myrbetriq | Mirabegron | 32 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 13 |
| Daptomycin | Daptomycin | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 28 | 20 |
| Irbesartan | Irbesartan | 28 | suppressed |
| Anastrozole | Anastrozole | 27 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 27 | suppressed |
| Testosterone | Testosterone | 27 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 18 |
| Topiramate | Topiramate | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | 16 |
| Finasteride | Finasteride | 25 | 15 |
| Risperidone | Risperidone | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | 12 |
| Lovastatin | Lovastatin | 24 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | 16 |
| Lacosamide | Lacosamide | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 19 |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Premarin | Estrogens, Conjugated | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Colchicine | Colchicine | 21 | 11 |
| Estradiol | Estradiol | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 15 |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 18 |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Ursodiol | Ursodiol | 17 | suppressed |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Glipizide | Glipizide | 16 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | 13 |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 15 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | 11 |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 11 |
| Cephalexin | Cephalexin | 13 | 13 |
| Cilostazol | Cilostazol | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 11 | suppressed |
| Mitigare | Colchicine | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,189.72 · 63 records | GlaxoSmithKline, LLC. | AIRSUPRA, AREXVY, Auvelity, CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, FARXIGA, GARDASIL 9, JARDIANCE, Kerendia, MOUNJARO, NUZYRA, Ozempic, PENMENVY, QULIPTA, RECORLEV, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, XHANCE, XIFAXAN, YUPELRI | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error